Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis (Q38404951)

2 September 2017

Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis (English)

1 reference

2 September 2017

1 reference

7

1 reference

2 September 2017

F Lanternier

1

1 reference

2 September 2017

S Poiree

2

1 reference

2 September 2017

C Elie

3

1 reference

2 September 2017

D Garcia-Hermoso

4

1 reference

2 September 2017

P Bakouboula

5

1 reference

2 September 2017

K Sitbon

6

1 reference

2 September 2017

M Wolff

8

1 reference

2 September 2017

P Ribaud

9

1 reference

2 September 2017

O Lortholary

10

1 reference

2 September 2017

French Mycosis Study Group

11

1 reference

2 September 2017

language of work or name

English

0 references

publication date

27 August 2015

1 reference

Journal of Antimicrobial Chemotherapy

2 September 2017

1 reference

2 September 2017

70

1 reference

2 September 2017

3116-3123

1 reference

2 September 2017

11

1 reference

Invasive zygomycosis in India: experience in a tertiary care hospital

2 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

Forty-one recent cases of invasive zygomycosis from a global clinical registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

Prospective antifungal therapy (PATH) alliance(®) : focus on mucormycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

Increasing incidence of mucormycosis in University Hospital, Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

Epidemiology and outcome of zygomycosis: a review of 929 reported cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

Combination antifungal therapy for invasive aspergillosis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: an useful tool for diagnosis and assessment of outcome in clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV236

21 January 2018

Identifiers

DOI

10.1093/JAC/DKV236

1 reference

2 September 2017

1 reference